Raynier Devillier

3.3k total citations
84 papers, 1.5k citations indexed

About

Raynier Devillier is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Raynier Devillier has authored 84 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Hematology, 30 papers in Immunology and 23 papers in Oncology. Recurrent topics in Raynier Devillier's work include Hematopoietic Stem Cell Transplantation (62 papers), Acute Myeloid Leukemia Research (35 papers) and Immune Cell Function and Interaction (21 papers). Raynier Devillier is often cited by papers focused on Hematopoietic Stem Cell Transplantation (62 papers), Acute Myeloid Leukemia Research (35 papers) and Immune Cell Function and Interaction (21 papers). Raynier Devillier collaborates with scholars based in France, Italy and Belgium. Raynier Devillier's co-authors include Didier Blaise, Mandy Brecqueville, Julien Mozziconacci, Véronique Gelsi‐Boyer, Daniel Birnbaum, Anne Murati, Norbert Vey, Christian Chabannon, Luca Castagna and Angéla Granata and has published in prestigious journals such as Blood, Cancer and Clinical Cancer Research.

In The Last Decade

Raynier Devillier

76 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Raynier Devillier France	23	1.1k	478	432	314	278	84	1.5k
Steve Kornblau United States	10	1.2k 1.1×	404 0.8×	369 0.9×	222 0.7×	253 0.9×	16	1.4k
Ram Malladi United Kingdom	20	935 0.8×	442 0.9×	366 0.8×	248 0.8×	156 0.6×	64	1.4k
Helmut Renges Germany	24	1.3k 1.2×	399 0.8×	477 1.1×	289 0.9×	215 0.8×	41	1.6k
Maurizio Miglino Italy	18	737 0.7×	291 0.6×	319 0.7×	220 0.7×	260 0.9×	65	1.1k
John D. McMannis United States	18	900 0.8×	605 1.3×	420 1.0×	247 0.8×	270 1.0×	57	1.4k
Édouard Forcade France	18	674 0.6×	372 0.8×	441 1.0×	138 0.4×	195 0.7×	105	1.2k
Jean Henri Bourhis France	13	1.2k 1.1×	364 0.8×	328 0.8×	232 0.7×	179 0.6×	28	1.3k
Firoozeh Sahebi United States	17	1.1k 1.0×	238 0.5×	574 1.3×	398 1.3×	202 0.7×	43	1.4k
Zhen‐Huan Hu United States	12	617 0.6×	150 0.3×	335 0.8×	211 0.7×	230 0.8×	44	955
Monic J. Stuart United States	15	953 0.9×	443 0.9×	431 1.0×	179 0.6×	456 1.6×	26	1.5k

Countries citing papers authored by Raynier Devillier

Since Specialization

Citations

This map shows the geographic impact of Raynier Devillier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raynier Devillier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raynier Devillier more than expected).

Fields of papers citing papers by Raynier Devillier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raynier Devillier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raynier Devillier. The network helps show where Raynier Devillier may publish in the future.

Co-authorship network of co-authors of Raynier Devillier

This figure shows the co-authorship network connecting the top 25 collaborators of Raynier Devillier. A scholar is included among the top collaborators of Raynier Devillier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raynier Devillier. Raynier Devillier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chevret, Sylvie, Xavier Poiré, Magalie Joris, et al.. (2024). Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Bone Marrow Transplantation. 59(7). 965–973.

Forcade, Édouard, Marie Robin, Marie‐Thérèse Rubio, et al.. (2024). IDALLO study: A retrospective multicenter study of the SFGM‐TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1‐mutated AML after allogeneic hematopoietic cell transplantation. HemaSphere. 8(3). e44–e44.

Fürst, Sabine, Boris Calmels, Thomas Pagliardini, et al.. (2023). GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. 58(11). 1179–1181. 2 indexed citations

Devillier, Raynier, Régis Peffault de Latour, Patrice Chevallier, et al.. (2023). SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: SI101-02 First-in-Human Phase I/II. Blood. 142(Supplement 1). 4861–4861. 1 indexed citations

Devillier, Raynier, Lionel Galicier, Gilles Piana, et al.. (2022). Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore). British Journal of Haematology. 199(1). 106–116. 2 indexed citations

Bernard, P, Rebecca B. Delconte, Sonia Pastor, et al.. (2022). Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity. Journal for ImmunoTherapy of Cancer. 10(5). e004244–e004244. 48 indexed citations

Rochigneux, Philippe, Aaron Lisberg, Alejandro J. Garcia, et al.. (2022). Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. Clinical Cancer Research. 28(23). 5136–5148. 20 indexed citations

Devillier, Raynier, Édouard Forcade, Alice Garnier, et al.. (2021). In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Advances. 6(6). 1804–1812. 17 indexed citations

Malard, Florent, Michaël Loschi, Faézeh Legrand, et al.. (2020). Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program. Blood. 136(Supplement 1). 15–15. 4 indexed citations

10.

Mariotti, Jacopo, Raynier Devillier, Stéfania Bramanti, et al.. (2019). Peripheral Blood Stem Cells versus Bone Marrow for T Cell–Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 25(9). 1810–1817. 13 indexed citations

11.

Devillier, Raynier, Faézeh Legrand, Jérôme Rey, et al.. (2018). HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison. Biology of Blood and Marrow Transplantation. 24(7). 1449–1454. 30 indexed citations

12.

Wang, Xuan, Raynier Devillier, Ming Wan, et al.. (2018). Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes. Bone Marrow Transplantation. 54(3). 458–464. 9 indexed citations

13.

Faucher, Catherine, Christian Chabannon, Sabine Fürst, et al.. (2018). Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. Bone Marrow Transplantation. 53(9). 1096–1104. 17 indexed citations

14.

Castagna, Luca, Alberto Mussetti, Raynier Devillier, et al.. (2017). Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation. 23(9). 1549–1554. 23 indexed citations

15.

Harbi, Samia, Raynier Devillier, Stéfania Bramanti, et al.. (2017). Haploidentical Hematopoietic Stem Cell Allogeneic Transplantation with High Dose Post Transplantation Cyclophosphamide for Patients over 60 Years of Age. Blood. 130. 2035–2035. 1 indexed citations

16.

Nunès, Jacques A., Céline Castanier, Raynier Devillier, et al.. (2014). Constitutive AKT activation in follicular lymphoma. BMC Cancer. 14(1). 565–565. 17 indexed citations

17.

Devillier, Raynier, Sabine Fürst, Roberto Crocchiolo, et al.. (2014). Poor Outcome with Nonmyeloablative Conditioning Regimen before Cord Blood Transplantation for Patients with High-Risk Acute Myeloid Leukemia Compared with Matched Related or Unrelated Donor Transplantation. Biology of Blood and Marrow Transplantation. 20(10). 1560–1565. 8 indexed citations

18.

Devillier, Raynier, Sabine Fürst, Jean El Cheikh, et al.. (2013). Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 20(3). 370–374. 34 indexed citations

19.

Devillier, Raynier, Luca Castagna, Jean El Cheikh, et al.. (2012). TLI in refractory chronic GVHD. Bone Marrow Transplantation. 48(6). 854–858. 6 indexed citations

20.

Prébet, Thomas, Anne Etienne, Raynier Devillier, et al.. (2010). Improved outcome of patients with low‐ and intermediate‐risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine. Cancer. 117(5). 974–981. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact